These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 26052689)

  • 1. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
    Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
    Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
    Fornaro L; Vivaldi C; Cereda S; Leone F; Aprile G; Lonardi S; Silvestris N; Santini D; Milella M; Caparello C; Musettini G; Pasquini G; Falcone A; Brandi G; Sperduti I; Vasile E;
    J Exp Clin Cancer Res; 2015 Dec; 34():156. PubMed ID: 26693938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
    Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
    Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
    Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.
    Huggett MT; Passant H; Hurt C; Pereira SP; Bridgewater J; Mukherjee S
    Tumori; 2014; 100(2):219-24. PubMed ID: 24852869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
    Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
    Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
    Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
    Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.
    Zheng Y; Tu X; Zhao P; Jiang W; Liu L; Tong Z; Zhang H; Yan C; Fang W; Wang W
    Br J Cancer; 2018 Aug; 119(3):291-295. PubMed ID: 29955136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
    Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
    Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
    Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
    Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
    Park K; Kim KP; Park S; Chang HM
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
    Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
    Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
    Larsen FO; Markussen A; Diness LV; Nielsen D
    Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.